Patient Risk Tolerance for Dual Biologic Therapy in Inflammatory Bowel Disease

The study on patient risk tolerance for dual biologic therapy (DBT) in inflammatory bowel disease (IBD) revealed several important insights into how patients with Crohn's disease (CD) and ulcerative colitis (UC) weigh the benefits and risks of treatment. Here is a detailed breakdown:

1. Willingness to Accept Risk for Better Efficacy

• Patients demonstrated a clear willingness to accept significant risks, including the risk of serious infections, if it meant achieving meaningful improvements in remission rates.
• Specifically, patients were willing to accept up to a 17.5% risk of serious infection to improve the probability of remission from 50% to 70%.
• This highlights the high value patients place on achieving remission, even in the context of potentially severe side effects.

2. Efficacy as a Key Driver

• Across all patient groups, the chance of remission was a primary factor influencing treatment decisions. The possibility of achieving better disease control was prioritized over other considerations, such as treatment type.

3. Safety as a Top Priority

• Despite their willingness to accept risks for better efficacy, safety concerns—particularly the risk of serious infection—were still the most important attribute overall in treatment decision-making.
• This underscores the delicate balance between the desire for improved outcomes and the apprehension about adverse effects.

4. Differences Between CD and UC Patients

• Crohn’s disease patients were more willing to accept higher infection risks in exchange for greater efficacy compared to ulcerative colitis patients. This difference may reflect variations in disease burden, treatment experiences, or perceived severity between the two conditions.

5. Preference for DBT vs. Monotherapy

• Interestingly, patients did not show a strong preference for dual biologic therapy (DBT) over biologic monotherapy. This suggests that the type of therapy itself was less important than its ability to deliver effective and safe outcomes.

6. Strong Aversion to Corticosteroids

• Patients expressed a strong dislike for corticosteroids, even when presented with scenarios involving zero risk of serious infection. This reflects the negative experiences and long-term side effects often associated with steroid use in IBD management.

7. Quantified Risk Tolerance

• The study quantified risk tolerance, providing valuable insights into the trade-offs patients are willing to make. This information can guide clinicians and researchers in designing treatment strategies and clinical trials that align with patient priorities.

8. Clinical Implications

• The findings emphasize the importance of incorporating patient preferences and risk tolerance into treatment planning for IBD. Shared decision-making is critical to ensure that therapies are tailored to individual needs and values.
• The study also provides direct guidance for designing and interpreting clinical trials of dual biologic therapies, ensuring that outcomes align with patient expectations.

9. Real-World Relevance

• The study recruited patients from a physician-verified IBD registry, ensuring that the findings are highly relevant to real-world clinical practice. All participants represented a difficult-to-treat population, having failed or currently receiving advanced therapies.

Conclusion:

Patients with IBD, especially those with prior treatment failures, are willing to accept substantial risks for treatments that offer higher chances of remission. While safety remains a top priority, efficacy is a key driver of treatment choices, and corticosteroids are strongly disliked. These insights underline the importance of personalized treatment strategies and shared decision-making, particularly for advanced therapies like dual biologic therapy.